Molecular MR Imaging of Hepatic Fibrogenesis

肝纤维化的分子磁共振成像

• 批准号: 10360979
• 负责人: Peter D Caravan
• 金额: $ 13.11万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-03 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10360979
• 关键词: Adult; Alcoholic Liver Cirrhosis; Animal Model; Atrial Fibrillation; Benign; Biopsy; Chemicals; Chronic Disease; Chronic Hepatitis; Cicatrix; Cirrhosis; Clinical Research; Clinical Trials; Collagen; Diabetic Nephropathy; Diagnosis; Diagnostic; Disease; Disease Progression; Fatty acid glycerol esters; Fibrosis; Financial Hardship; Goals; Healthcare; Hepatic Fibrogenesis; Hepatocyte; Human; Hypertrophic Cardiomyopathy; Image; Inflammation; Life Style; Liver; Liver Fibrosis; Liver diseases; Magnetic Resonance; Magnetic Resonance Imaging; Methods; Modeling; Modification; Molecular; Monitor; Morbidity - disease rate; Outcome; Oxides; Patients; Pharmacotherapy; Primary carcinoma of the liver cells; Prognosis; Pulmonary Fibrosis; Risk; Serum; Staging; Techniques; Tissues; Western World; biomarker panel; clinical practice; cost; diet and exercise; elastography; extracellular; fibrogenesis; imaging probe; improved; liver transplantation; mortality; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel therapeutics; patient stratification; prototype; response; tool; treatment response

Project Summary Nonalcoholic fatty liver disease (NAFLD) is the most prominent cause of liver disease, with 20-30% of adults in the western world now estimated to have NAFLD. In NAFLD, hepatocytes accumulate excess fat (steatosis), which is benign and reversible. However up to 30% of patients with NAFLD will develop non-alcoholic steatohepatitis (NASH) which is characterized by steatosis, inflammation, and scarring (fibrosis). Patients with only steatosis have good long-term prognosis, with no increased liver related morbidity or mortality, but those with NASH have increased risk of cirrhosis, hepatocellular carcinoma and mortality. NASH is expected to soon be the leading indication of liver transplantation. The financial burden of NAFLD/NASH is currently estimated to cost >$100 billion in the USA alone. There is an urgent need to identify NAFLD patients who are at risk of developing NASH and cirrhosis so as to better manage patient healthcare through improved lifestyle, exercise and diet. In addition, a large number of new therapies have entered clinical trials and effective diagnostics are needed to better stratify patients into these trials and to accurately monitor response to therapy. Fibrosis stage, and not steatosis nor inflammation, is the only feature of disease associated with worse outcomes in NASH. Besides biopsy we lack good tools to noninvasively detect liver fibrosis, stage fibrosis, or monitor response to treatment. Elastography methods are not sensitive to early changes in disease. Serum biomarkers and biomarker panels to identify NASH and/or liver fibrosis, are also limited and lack accuracy for staging. None of these techniques has the accuracy to monitor treatment. An accurate, safe method to diagnose and monitor NASH and associated fibrosis is of utmost importance in both clinical practice and clinical research. We recently demonstrated in animal models that we could quantify fibrogenesis (active disease) noninvasively using a molecular magnetic resonance (MR) probe, Gd-Hyd, that targets extracellular allysine, a chemical modification of oxidized collagen, present only during active fibrogenesis. We showed that Gd-Hyd imaging could detect fibrogenesis, monitor treatment response and could distinguish active fibrogenesis from stable scar in models of lung and liver fibrosis. The overall goal of this project is to improve on this prototype to develop an optimized fibrogenesis MR probe for robust, quantification of liver fibrogenesis in patients.

项目摘要 非酒精性脂肪性肝病（NAFLD）是肝脏疾病的最主要原因， 西方世界现在估计有NAFLD。在NAFLD中，肝细胞积累过量脂肪（脂肪变性）， 这是良性且可逆的。然而，高达30%的NAFLD患者将发展为非酒精性 脂肪性肝炎（NASH），其特征在于脂肪变性、炎症和瘢痕形成（纤维化）。患者 只有脂肪变性有良好的长期预后，没有增加肝脏相关的发病率或死亡率，但那些 NASH患者发生肝硬化、肝细胞癌和死亡率的风险增加。预计NASH将很快 是肝移植的主要指征。NAFLD/NASH的经济负担目前估计为 仅在美国就花费超过1000亿美元。目前迫切需要确定有风险的NAFLD患者。 发展NASH和肝硬化，以便通过改善生活方式、锻炼和治疗， 和饮食。此外，大量新疗法已进入临床试验，有效的诊断方法也在不断发展。 需要更好地将患者分层到这些试验中，并准确监测对治疗的反应。 纤维化阶段，而不是脂肪变性或炎症，是疾病恶化的唯一特征。 NASH的结果。除了活检，我们缺乏良好的工具来无创检测肝纤维化，分期纤维化，或 监测对治疗的反应。弹性成像方法对疾病的早期变化不敏感。血清 用于鉴定NASH和/或肝纤维化的生物标志物和生物标志物组也是有限的，并且缺乏针对NASH和/或肝纤维化的准确性。 分期付款这些技术都不具有监测治疗的准确性。一种准确、安全的诊断方法 并且监测NASH和相关的纤维化在临床实践和临床研究中都是极其重要的。 我们最近在动物模型中证明，我们可以非侵入性地量化纤维化（活动性疾病） 使用分子磁共振（MR）探针Gd-Hyd，靶向细胞外的赖氨酸，一种化学物质 氧化胶原蛋白的修饰，仅在活跃的纤维形成期间存在。我们发现钆氢造影可以 检测纤维化，监测治疗反应，并可以区分活动性纤维化与稳定性瘢痕， 肺和肝纤维化模型。这个项目的总体目标是改进这个原型， 优化的纤维化MR探头，用于对患者的肝纤维化进行稳健的量化。